These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22550115)

  • 1. Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations.
    Uwanyiligira M; Landry P; Genton B; de Valliere S
    Clin Infect Dis; 2012 Jul; 55(2):201-5. PubMed ID: 22550115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postexposure rabies prophylaxis completed in 1 week: preliminary study.
    Shantavasinkul P; Tantawichien T; Wilde H; Sawangvaree A; Kumchat A; Ruksaket N; Lohsoonthorn V; Khawplod P; Tantawichien T
    Clin Infect Dis; 2010 Jan; 50(1):56-60. PubMed ID: 19995217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabies postexposure management of travelers presenting to travel health clinics in Auckland and Hamilton, New Zealand.
    Shaw MT; O'Brien B; Leggat PA
    J Travel Med; 2009; 16(1):13-7. PubMed ID: 19192122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroconversion following incomplete human rabies postexposure prophylaxis.
    Robertson K; Recuenco S; Niezgoda M; Garcia EJ; Rupprecht CE
    Vaccine; 2010 Sep; 28(39):6523-6. PubMed ID: 20637309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human rabies post exposure prophylaxis in Bhutan, 2005-2008: trends and risk factors.
    Tenzin ; Dhand NK; Ward MP
    Vaccine; 2011 May; 29(24):4094-101. PubMed ID: 21497633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabies Vaccine and Rabies Immunoglobulin in Cambodia: Use and Obstacles to Use.
    Tarantola A; Ly S; In S; Ong S; Peng Y; Heng N; Buchy P
    J Travel Med; 2015; 22(5):348-52. PubMed ID: 26173470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabies postexposure consultations in New Zealand from 1998 to 2012.
    Shaw MT; Visser J; Edwards C
    J Travel Med; 2015; 22(1):31-8. PubMed ID: 25315202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
    Gogtay NJ; Munshi R; Ashwath Narayana DH; Mahendra BJ; Kshirsagar V; Gunale B; Moore S; Cheslock P; Thaker S; Deshpande S; Karande S; Kumbhar D; Ravish HS; Harish BR; Pisal SS; Dhere R; Parulekar V; Blackwelder WC; Molrine DC; Kulkarni PS
    Clin Infect Dis; 2018 Jan; 66(3):387-395. PubMed ID: 29020321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers".
    Ranney M; Partridge R; Jay GD; Rozzoli DE; Pandey P
    J Travel Med; 2006; 13(6):329-33. PubMed ID: 17107424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postexposure prophylaxis for rabies in resource-limited/poor countries.
    Shantavasinkul P; Wilde H
    Adv Virus Res; 2011; 79():291-307. PubMed ID: 21601051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabies postexposure prophylaxis in returned injured travelers from France, Australia, and New Zealand: a retrospective study.
    Gautret P; Shaw M; Gazin P; Soula G; Delmont J; Parola P; Soavi MJ; Brouqui P; Matchett DE; Torresi J
    J Travel Med; 2008; 15(1):25-30. PubMed ID: 18217866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults.
    Gogtay N; Thatte U; Kshirsagar N; Leav B; Molrine D; Cheslock P; Kapre SV; Kulkarni PS;
    Vaccine; 2012 Nov; 30(50):7315-20. PubMed ID: 23010601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-exposure rabies prophylaxis in humans exposed to animals in Lublin province (Eastern Poland) in 2012-2015 - A retrospective study.
    Krzowska-Firych J; Tomasiewicz K; Kozøowska A
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-6. PubMed ID: 28166482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabies postexposure prophylaxis in a UK travel clinic: ten years' experience.
    Wijaya L; Ford L; Lalloo D
    J Travel Med; 2011; 18(4):257-61. PubMed ID: 21722237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using serology to assist with complicated post-exposure prophylaxis for rabies and Australian bat lyssavirus.
    Conroy N; Vlack S; Williams JM; Patten JJ; Horvath RL; Lambert SB
    PLoS Negl Trop Dis; 2013; 7(2):e2066. PubMed ID: 23469301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis.
    Tantawichien T; Sibunruang S; Tantawichien T; Angsanakul J; Benjavongkulchai M; Limsuwan K; Udomchaisakul P; Khomvilai S; Sitprija V
    Expert Rev Vaccines; 2014 Dec; 13(12):1593-601. PubMed ID: 25315021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should travellers to rabies-endemic countries be pre-exposure vaccinated? An assessment of post-exposure prophylaxis and pre-exposure prophylaxis given to Danes travelling to rabies-endemic countries 2000-12.
    Christiansen AH; Rodriguez AB; Nielsen J; Cowan SA
    J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27147729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradermal pre-exposure rabies immunisation in New Zealand.
    Shaw MM; Leggat PA; Williams ML
    Travel Med Infect Dis; 2006 Jan; 4(1):29-33. PubMed ID: 16887722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of delay in initiating post-exposure prophylaxis for rabies prevention among animal bite cases: hospital based study.
    Joseph J; N S; Khan AM; Rajoura OP
    Vaccine; 2013 Dec; 32(1):74-7. PubMed ID: 24188758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.